Cover Image
市場調查報告書

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品分析

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364838
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品分析 Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 50 Pages
簡介

本報告提供以葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2)的概要

治療藥的開發

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各開發階段

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各治療範圍

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中的產品 - 各適應症

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :企業開發中的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2)的治療藥開發企業

  • Advinus Therapeutics Ltd
  • Amgen Inc.
  • Hua Medicine (Shanghai) Ltd.
  • LG Life Science LTD.
  • Ligand Pharmaceuticals, Inc.
  • Novartis AG
  • Poxel SA
  • 武田藥品工業
  • TEIJIN FIBERS製藥
  • vTv Therapeutics Inc
  • Yuhan Corporation

藥物簡介

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :暫停中的計劃

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :開發中止的產品

葡萄糖激酶 (己糖激酶D或己糖激酶IV或EC 2.7.1.2) :主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1047TDB

Summary:

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2017, outlays comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Glucokinase is an enzyme that catalyzes the initial step in utilization of glucose by the beta-cell and liver at physiological glucose concentration. The role of GCK is to provide G6P for the synthesis of glycogen. Pancreatic glucokinase plays an important role in modulating insulin secretion. Hepatic glucokinase helps to facilitate the uptake and conversion of glucose by acting as an insulin-sensitive determinant of hepatic glucose usage. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders which include indications Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes) and Obesity.

Furthermore, this report also reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
  • The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Overview
    • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Eli Lilly and Co
    • Ligand Pharmaceuticals Inc
    • Merck & Co Inc
    • Poxel SA
    • Teijin Pharma Ltd
    • vTv Therapeutics Inc
    • Yuhan Corp
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles
    • AM-9514 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2608204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sinogliatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMG-123 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTP-399 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-GKA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Products
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products
  • Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 17, 2016: Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug
      • Aug 10, 2016: vTv Therapeutics Announces Positive Topline Results From Phase 2B Study Of Glucokinase Activator TTP399 In Type 2 Diabetes
      • Jun 14, 2016: vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions
      • Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity
      • Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes
      • Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial
      • Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes
      • Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug
      • Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control
      • Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics
      • Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients
      • Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial
      • Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013
      • Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by Eli Lilly and Co, H2 2017
  • Pipeline by Ligand Pharmaceuticals Inc, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Poxel SA, H2 2017
  • Pipeline by Teijin Pharma Ltd, H2 2017
  • Pipeline by vTv Therapeutics Inc, H2 2017
  • Pipeline by Yuhan Corp, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administrations, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top